LexaGene Closes Multiple MiQLab Sales BEVERLY, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen...

LexaGene Completes Analytical Studies for FDA EUA of COVID-19 Testing BEVERLY, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...

LexaGene Enters into Cooperative Research and Development Agreement with the United States Army’s Combat Capabilities Development Command BEVERLY, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen...

LexaGene’s MiQLab™ System Featured at Three Key Veterinary Tradeshows September 7-9, WVC 93rd Annual Conference, Las Vegas, NVSeptember 12-14, International Veterinary Emergency and Critical Care, Nashville, TNSeptember 23-26, Southwest Veterinary Symposium, San...

LexaGene Demonstrates a Simple and Inexpensive Multiplex PCR Chemistry with Shorter Lead Times for use on its MiQLab System First point-of-need, PCR system capable of using conventional probe-based chemistry or inexpensive, rapidly available SYBR Green chemistry BEVERLY, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- LexaGene...